870536-26-8Relevant academic research and scientific papers
Practical synthesis of p- and o-amino- and methoxyphenolic anthraquinones
Nicolaou,Lu, Min,Chen, Pengxi,Shah, Akshay A.
, p. 12687 - 12691 (2015)
New versatile and selective methods for the syntheses of substituted amino- and methoxyphenolic anthraquinones (I-IV) based on fusion of cyanophthalides (V) and semiquinone aminals (VI, VII) under basic conditions are described. Fusion: 3-Cyanophthalides (V) react with substituted amino semiquinone aminals (VI, VII) under basic conditions to provide selectively a diverse array of substituted amino- and methoxyphenolic anthraquinones (I-IV).
Discovery and structure-guided optimization of tert-butyl 6-(phenoxymethyl)-3-(trifluoromethyl)benzoates as liver X receptor agonists
Matsui, Yumi,Yamaguchi, Takahiro,Yamazaki, Takanori,Yoshida, Masayuki,Arai, Masami,Terasaka, Naoki,Honzumi, Shoko,Wakabayashi, Kenji,Hayashi, Shinko,Nakai, Daisuke,Hanzawa, Hiroyuki,Tamaki, Kazuhiko
, p. 3914 - 3920 (2015/08/24)
Abstract To obtain potent liver X receptor (LXR) agonists, a structure-activity relationship study was performed on a series of tert-butyl benzoate analogs. As the crystal structure analysis suggested applicable interactions between the LXR ligand-binding
TISSUE FACTOR PRODUCTION INHIBITOR
-
Page/Page column 85, (2010/11/26)
A medicament which has an activity of inhibiting production of tissue factor and comprises an LXR ligand as an active ingredient; and a medicament for treatment and/or prophylaxis of vascular restenosis following angioplasty, endarterectomy, percutaneous transluminal coronary angioplasty (PTCA) or stent implantation, or treatment and/or prophylaxis of blood coagulation diseases, diseases induced by platelet aggregation including stable or unstable angina pectoris, cardiovascular and cerebrovascular diseases including thromboembolism formation diseases accompanying diabetes, rethrombosis following thrombolysis, cerebral ischemic attack, infarction, stroke, ischemia-derived dementia, peripheral artery disease, thromboembolism formation diseases during use of an aorta-coronary artery bypass, glomerulosclerosis, renal embolism, tumor or cancer metastasis, which comprises an LXR ligand as an active ingredient.
